3D Printed Drugs Market Like to Hit $522 Million by 2030

Dysphagia is more prevalent in geriatric population and children, which results in difficulty while swallowing. 3D printed drugs are gaining popularity, as FDA has passed a priority review voucher system for it. In addition, increase in the geriatric population and technological advancement in 3D pointing procedures are expected to contribute towards the growth of the market.

The potential market for other 3D printed drugs (moderate growth scenario) is estimated to be $278 million in 2020 and would reach $522 million by 2030, growing at a CAGR of 6.5% from 2020 to 2030. The U.S. market holds the highest market share in 2020.

3D printed drugs are medications created by 3D printing technology that are used to treat patients suffering from dysphagia. 3D printed drugs have porous structures that can disintegrate rapidly inside the mouth itself. Aprecia Pharmaceuticals Company SPRITAM levetiracetam is the first 3D printed drug, which has been approved by the U.S. Food and Drug Administration (FDA) in August 2015.

Download PDF Report Sample with statistical info @ https://www.alliedmarketresearch.com/request-sample/4508

Constant technological developments in 3D printing techniques, a rise in the incidence of epilepsy cases, and an increase in awareness about 3D printing technology in the developing countries drive the growth of the market. However, lack of government regulations related to these drugs and adverse effects of 3D printed drugs are expected to limit the market growth.

The global 3D printed drugs market is analyzed based on forecast scenarios such as low growth scenario, moderate growth scenario, and rapid growth scenario.

According to a low growth scenario, the U.S. is anticipated to account for the highest market share in 2020, and the rest of the North American market is expected to grow at the highest rate, registering the CAGR of 5.1% by 2030.

The key players profiled in this report include Aprecia Pharmaceuticals, GlaxoSmithKline Plc., Hewlett Packard Caribe, BV, LLC, 3D Printer Drug Machine, and FabRx Ltd.

The organizations engaged in the research of 3D printed drugs included in this report are UCL School of Pharmacy, University of Glasgow, University College London, The University of Nottingham, and the National University of Singapore.

Europe is estimated to account for a four-sevenths share in 2020 and is expected to dominate the market throughout the forecast period, due to the presence of well-established healthcare systems and an increase in the prevalence of dysphagia. In addition, the increase in the adoption of 3D printed drugs is anticipated to provide new growth opportunities for the key players in the European market.

However, Asia-Pacific is projected to grow at the highest growth rate during the analysis period, owing to an increase in healthcare expenditure, a rise in awareness related to 3D printing technique, presence of large patient pool, and developments in healthcare infrastructure.

Make an Enquiry for Purchase Report @ https://www.alliedmarketresearch.com/purchase-enquiry/4508

Key Findings of the 3D Printed Drugs Market:
• In North America, the U.S. is anticipated to dominate the market in 2020, whereas the rest of North America is projected to grow at the highest CAGR during the forecast period.
• Germany was the major shareholder in the European 3D printed drugs market in 2016.
• Asia-Pacific is expected to register the highest growth rate in the future.
• Australia is expected to grow at the highest CAGR in the Asia-Pacific 3D printed drugs market.

Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975

help@alliedmarketresearch.com

About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

This release was published on openPR.